Sanofi inks $470M Vigil buyout, brushing off rivals’ failures to join Novartis in Alzheimer’s race
Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. With the biotech into the last year of its cash runway, Sanofi has swept in to secure a small molecule that could challenge Novartis for the Alzheimer’s disease market.
Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. With the biotech into the last year of its cash runway, Sanofi has swept in to secure a small molecule that could challenge Novartis for the Alzheimer’s disease market.
